TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3907967
Drug: Norethisterone oenanthate
Normalized name: Oenanthic acid
DrugBank: Norethindrone enanthate (DB14678)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norethisterone oenanthate (NET OEN) 50 mg with estradiol valerate (E2 Val.) 2.5 mg or estradiol cypionate (E2 Cyp.)
Study: 31483461
Drug: Short-term Treatment
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term Treatment for Internet and Computer Game Addiction
Study: 30152068
Drug: Intravaginal progesterone‐releasing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravaginal progesterone‐releasing device (IVD) containing 0.78 g progesterone and saline (low P4 concentration)
Study: 30152068
Drug: Intravaginal progesterone‐releasing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravaginal progesterone‐releasing device (IVD) containing 1.56 g progesterone (high P4 concentration)
Study: 22214276
Drug: BDP‐HFA (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: BDP‐HFA (100 μg twice daily)
Study: 19581539
Drug: Temsirolimus 175
Normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Temsirolimus 175 mg weekly for 3 weeks followed by 75 mg weekly
Study: 19581539
Drug: Temsirolimus 175
Normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Temsirolimus 175 mg weekly for 3 weeks followed by 25 mg weekly
Study: 15362749
Drug: Budesonide foam
Normalized name: budesonide Rectal Foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide foam (2 mg/50 mL)
Study: 15362749
Drug: Betamethasone enema
Normalized name: betamethasone Enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betamethasone enema (5 mg/100 mL)
Study: 11458140
Drug: Sham therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham therapy (same procedure without effective denervation)
Study: 8420421
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg ICI 204,219 orally
Study: 3535695
Drug: 3 ml
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 ml of 0.9% saline containing 1.5 mg PGE2
Study: 3535695
Drug: 3 ml
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 ml of 0.9% saline (placebo)
Study: 21419317
Drug: Mixed-grain dietary
Normalized name: barley grain
DrugBank: Barley (DB10506)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed-grain dietary product (MG)
Study: 16517534
Drug: Piperacillin/tazobactam (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin/tazobactam (80 mg/kg every 6 h, max 4.5 g/dose)
Study: 16517534
Drug: Cefepime (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefepime (50 mg/kg every 8 h, max 2 g/dose)
Study: 1601598
Drug: Home rehabilitation
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home rehabilitation with planned physical therapy
Study: 3547214
Drug: Oral salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral salbutamol therapy
Study: 3547214
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no betamimetic agents)
Study: 27739087
Drug: Tonic infusion
Normalized name: Ellis Tonic
DrugBank: Zinc sulfate, unspecified form (DB14548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tonic infusion of hypertonic saline into the right anterior temporalis muscle
Study: 25721866
Drug: OM‐89S (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: OM‐89S (6 mg daily for 10 days, placebo for 20 days)
Study: 25721866
Drug: Nitrofurantoin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrofurantoin (50 mg daily for 30 days)
Study: 23889885
Drug: Traumeel ointment
Normalized name: Traumeel Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traumeel ointment (T-O)
Study: 23889885
Drug: Traumeel gel
Normalized name: TRAUMEEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traumeel gel (T-G)
Study: 23889885
Drug: Diclofenac gel
Normalized name: diclofenac Topical Gel
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac gel (D-G)
Study: 23889885
Drug: Traumeel ointment
Normalized name: Traumeel Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traumeel ointment (T-O) and Traumeel gel (T-G)
Study: 20234828
Drug: Atomoxetine 2.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine 2.4 mg/kg/day
Study: 11421997
Drug: Lamotrigine 100
Normalized name: lamotrigine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamotrigine 100 mg single dose
Study: 11421997
Drug: Lamotrigine 100
Normalized name: lamotrigine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamotrigine 100 mg single dose in severe cirrhosis (Child-Pugh grade B)
Study: 11421997
Drug: Lamotrigine 100
Normalized name: lamotrigine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamotrigine 100 mg single dose in severe cirrhosis (Child-Pugh grade C)
Study: 9014993
Drug: Dofetilide (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dofetilide (both doses)
Study: 8344127
Drug: Prednisone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (1 mg.kg‐1.day‐1 for 10 days, then 0.3 mg.kg‐1.day‐1 for 50 days)
Study: 15811647
Drug: Evidence-based lecture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evidence-based lecture on the benefits of the polio vaccine
Study: 10587936
Drug: Enhanced Abbreviated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced Abbreviated treatment
Study: 10587936
Drug: 12-month course
Normalized name: moth bean
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-month course of treatment (including at least 6 months in a therapeutic community followed by outpatient treatment)
Study: 31957654
Drug: Cardiac rehabilitation
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac rehabilitation (CR) for 6 months, including once weekly 90-minute in-facility exercise sessions and 4 days per week at-home exercise sessions.
Study: 28144724
Drug: Nasal naloxone
Normalized name: naloxone Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal naloxone 0.8 mg
Study: 28144724
Drug: Nasal naloxone
Normalized name: naloxone Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal naloxone 1.6 mg
Study: 28144724
Drug: Intravenous naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous naloxone 1.0 mg
Study: 22002479
Drug: Spontaneous clearance
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spontaneous clearance (no treatment)
Study: 17127224
Drug: Moxifloxacin 400
Normalized name: moxifloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin 400 mg administered as a single dose in a 1 hour infusion (250 ml) for perioperative prophylaxis
Study: 9388809
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group membership (collaborative recall task)
Study: 28830881
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (current dose for the first 12 months)
Study: 26397083
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (continued physical therapy)
Study: 23357640
Drug: Mud therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mud therapy (11 consecutive sessions of peloids applied to the knee)
Study: 23357640
Drug: Routine drug
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine drug treatment (Control group)
Study: 11952546
Drug: Standard psoriasis
Normalized name: MG 217 Psoriasis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard psoriasis treatment alone
Study: 30658546
Drug: Manualised treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manualised treatment
Study: 23757615
Drug: SITA/MET FDC
Approvals — FDA: no, EMA: no, PMDA: no
Description: SITA/MET FDC 50/500 mg b.i.d. (uptitrated to 50/1,000 mg b.i.d.)
Study: 23757615
Drug: MET 500
Normalized name: cefetamet 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: MET 500 mg b.i.d. (uptitrated to 1,000 mg b.i.d.)
Study: 19628939
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy (weekly sessions of individual, receptive music therapy using the validated 'U' technique)
Study: 17259554
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine therapy combined with growth factor pathway inhibitors
Study: 17259554
Drug: Selective estrogen
Normalized name: Selective estrogen receptor modulator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective estrogen receptor modulator tamoxifen
Study: 17259554
Drug: Pure ER
Normalized name: Dream Pure BB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pure ER antagonists
Study: 15235928
Drug: Mizoribine (MZ)
Normalized name: Mizoribine
DrugBank: Mizoribine (DB12617)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mizoribine (MZ) onlay therapy
Study: 11763976
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of 400 microg misoprostol, 8 h before aspiration
Study: 11763976
Drug: Vaginal self‐administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal self‐administration of 400 microg misoprostol, 4 h before aspiration
Study: 9409230
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acids (5 g eicosapentaenoic acid and docosahexaenoic acid per day)
Study: 9409230
Drug: Antioxidants (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidants (75 mg vitamin E, 150 mg vitamin C, 15 mg beta-carotene, and 30 mg coenzyme Q10 per day)
Study: 3321849
Drug: Cisapride (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride (4 mg, i.v. injection)
Study: 27357095
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (ZnC + colostrum)
Study: 23311173
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese Medicines (Xiaozhi decoction), twice daily for 6 weeks
Study: 23311173
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine (0.5 g azithromycin for 3 days, 6 courses of treatment, each course lasting 4 days)
Study: 20624316
Drug: 30-minute daily
Normalized name: lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 30-minute daily physical education sessions based on early psychomotor education
Study: 20624316
Drug: 30-minute daily
Normalized name: lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 30-minute daily physical education sessions
Study: 18179460
Drug: Flexible-dose sildenafil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flexible-dose sildenafil for ED treatment
Study: 16565867
Drug: Telemedicine support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telemedicine support (Health Buddy computer providing daily Internet-based support)
Study: 12037369
Drug: Experimental dentifrice
Normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Experimental dentifrice formulation containing stannous fluoride (SnF(2))
Study: 12037369
Drug: Experimental dentifrice
Normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Experimental dentifrice formulation containing sodium fluoride (NaF)
Study: 8573730
Drug: Manidipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manidipine (20 mg/day)
Study: 2128700
Drug: Requirement-adapted peripheral-venous
Normalized name: bushmaster venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Requirement-adapted peripheral-venous parenteral nutrition with maltose and fat emulsion (650 mosm/l; 2,000 kcal)
Study: 2128700
Drug: Common requirement-adapted
Normalized name: Common carp
DrugBank: Common carp (DB10614)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Common requirement-adapted parenteral nutrition regimen via central-venous catheter (2,000 mosm/l; 2,000 kcal)
Study: 29173735
Drug: Lurasidone 20
Normalized name: lurasidone 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lurasidone 20 to 80 mg/day
Study: 25500487
Drug: canagliflozin (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: canagliflozin (all doses)
Study: 17153881
Drug: Beta-glucuronidase (BG)
Normalized name: Recombinant human beta-glucuronidase
DrugBank: Vestronidase alfa (DB12366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Beta-glucuronidase (BG) treatment
Study: 11185629
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of [14C]telmisartan 40 mg
Study: 11185629
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of [14C]telmisartan 40 mg
Study: 11185629
Drug: Both oral
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both oral and intravenous administration
Study: 6434117
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose antacid (10 ml as required)
Study: 6434117
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose placebo
Study: 6434117
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose antacid (30 ml seven times daily)
Study: 6434117
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose placebo
Study: 27085660
Drug: Carotid Endarterectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carotid Endarterectomy (CEA) plus Best Medical Treatment (BMT)
Study: 27085660
Drug: Carotid Artery
Normalized name: Sus scrofa artery preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carotid Artery Stenting (CAS) plus Best Medical Treatment (BMT)
Study: 27085660
Drug: Best Medical
Normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best Medical Treatment (BMT) alone
Study: 7612715
Drug: Oral feeding
Normalized name: SET,FEEDING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral feeding ad libitum (control group)
Study: 29741754
Drug: Probiotics (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics (2 capsules of Lactobacillus rhamnosus GG daily for 6 months)
Study: 26674898
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g (2 × 500 mg) tranexamic acid tablets before surgery
Study: 25140000
Drug: First-line chemotherapy
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line chemotherapy combined with bevacizumab
Study: 18626295
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) + imipramine
Study: 18626295
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) + placebo
Study: 8965037
Drug: Topical steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical steroid injection
Study: 8965037
Drug: Deltoid muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deltoid muscle injection
Study: 1743321
Drug: 5 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 micrograms GnRH pulse dose
Study: 1743321
Drug: 10 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 micrograms GnRH pulse dose
Study: 1743321
Drug: 20 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 micrograms GnRH pulse dose
Study: 30586746
Drug: ALD-401 infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ALD-401 infusion
Study: 29070115
Drug: High-dose methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methotrexate combined with rituxan (targeted treatment group)
Study: 29070115
Drug: High-dose methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methotrexate combined with whole brain radiotherapy (traditional treatment group)
Study: 26091461
Drug: Dexmedetomidine (DEX)
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine (DEX) administered at a loading dose of 0.5 μg/kg for 10 minutes, followed by an infusion rate of 0.4 μg/kg/h from insufflation of the pneumoperitoneum to the end of surgery.
Study: 26091461
Drug: Dexmedetomidine (DEX)
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine (DEX) administered as described above.
Study: 23512419
Drug: Morphine 0.04
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 0.04 mg/kg iv followed by 0.01 mg/kg/h infusion for 24 h
Study: 19893121
Drug: Filgrastim (Neupogen)
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Filgrastim (Neupogen) administered systematically during antiviral therapy
Study: 19893121
Drug: Combination antiviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination antiviral therapy (pegylated interferon alfa plus ribavirin) without Filgrastim
Study: 17536485
Drug: Basal diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal diet supplemented with 9.05 mmol (220 mg) magnesium/d for 72 d
Study: 15449150
Drug: UFT 600
Normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT 600 mg/day preoperatively for 7 consecutive days
Study: 8988721
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no chemotherapy or radiotherapy)
Study: 9684137
Drug: Prolonged PPC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged PPC therapy
Study: 2541967
Drug: Treated capsules
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treated capsules (Nonoxynol-9)
Study: 2541967
Drug: Non-treated capsules
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-treated capsules (Nonoxynol-9)
Study: 29607658
Drug: Presence of
Normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presence of none of the conditions (mental illness, hazardous alcohol use, drug dependence)
Study: 29607658
Drug: Presence of
Normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presence of all three conditions (mental illness, hazardous alcohol use, drug dependence)
Study: 16231766
Drug: 25 microg
Normalized name: Digoxin 125 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 microg x h(‐1) fentanyl and 4 mg x h(‐1) ketamine
Study: 16231766
Drug: 35 microg
Normalized name: Ethinyl estradiol 35 microgram and norethindrone 1 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35 microg x h(‐1) subcutaneous fentanyl infusion
Study: 16231766
Drug: 50 microg
Normalized name: Digoxin 250 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 microg x h(‐1) subcutaneous fentanyl infusion
Study: 16231766
Drug: 25 microg
Normalized name: Digoxin 125 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 microg x h(‐1) fentanyl and 2 mg x h(‐1) ketamine
Study: 12220322
Drug: Carbamazepine (placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine (placebo add-on treatment)
Study: 1969567
Drug: Antihypertensive drugs
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive drugs (diuretics or beta-blockers)
Study: 7026258
Drug: Paracetamol (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (1000 mg i.v.)
Study: 28578427
Drug: 2.0 g
Normalized name: Fifty50 2.0 Glucose Meter
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 g glutamine administration
Study: 23648352
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for elevated serum muscle enzymes in HP patients
Study: 21849260
Drug: Carisbamate 1000
Normalized name: Chlorphenesin Carbamate
DrugBank: Chlorphenesin carbamate (DB14656)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carisbamate 1000 mg/day
Study: 21849260
Drug: Carisbamate 1500
Normalized name: Chlorphenesin Carbamate
DrugBank: Chlorphenesin carbamate (DB14656)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carisbamate 1500 mg/day
Study: 21849260
Drug: Carisbamate (<1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carisbamate (<1000 mg/day)
Study: 17245623
Drug: Imatinib mesylate
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imatinib mesylate plus hydroxyurea (500 mg twice a day)
Study: 11191092
Drug: Desogestrel (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desogestrel (150 microg orally daily) and testosterone pellets (2 x 200 mg per 12 weeks)
Study: 11191092
Drug: Desogestrel (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desogestrel (150 microg orally daily) and testosterone pellets (2 x 200 mg per 12 weeks) with finasteride (5 mg orally daily)
Study: 9682338
Drug: DTP +
Normalized name: DTP-348
DrugBank: DTP-348 (DB12741)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTP + PRP-T administered in separate injections (S-In group, n = 237)
Study: 7982415
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulphate (46-52 mmol/18-20 h)
Study: 7982415
Drug: Oral magnesium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral magnesium hydroxide (600 mg/day)
Study: 26457893
Drug: Interactive group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interactive group music therapy (n = 62; 20 units of 40 minutes, 2×/week)
Study: 26077620
Drug: Telephone Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone Cognitive Behavioral Therapy (T‐CBT)